TCBWF

0.00180.00%
ML

Mark L. Bonyhadi

Chairman of Scientific Advisory Board

Dr. Mark L. Bonyhadi, Ph.D., serves as Scientific Advisor of cTRL Therapeutics USA, Inc.He had been Non-Executive Independent Director of TC Biopharm (Holdings) Plc since February 2022 until June 26, 2024 and also serves as its Chairman of Scientific Advisory Board since May 2022. He is a Member of the scientific advisory Board for Akron Biotech and also serves as a Non-Executive Director at TCBP and as a Non-Executive Director at Integra Therapeutics. He is Independent Director at Integra Therapeutics SL since May 2022. He served as Senior Advisor at Qiming Venture Partners USA. Prior to joining Qiming in 2018, he held positions of Vice President of Research, Head of Academic Affairs and Vice President of Process Research Sciences from 2013-2018 at Juno Therapeutics. From 2006-2013, he was Director of Global Business Development for Cell Therapy at Invitrogen, which was merged with Applied BioSystems, to create Life Technologies, which subsequently was acquired by Thermo-Fisher. He was responsible for identifying and implementing business opportunities aligned with the Lifetech/Invitrogen/Thermo cellular medicine portfolio, participating and leading in the launch of the Cell Therapy Systems (CTS™) product line optimized for cell therapy applications, as well as working with academia and industry to accelerate the development of novel cell and/or gene-based therapies. From 1997-2005, he served as Director and later Vice President of Research at Xycte Therapies, a T cell therapy company treating cancer, infectious disease and autoimmunity. Prior to that, he was a senior scientist at SyStemix, a biotech company developing hematopoietic stem cell-based therapies for treating cancer, where he did his postdoctoral training. He is also the inventor on 11 patents and an author on 40 publications He received a B.A. from Reed College, Portland, OR (1982) and a PhD from University of California at Berkeley (1990), where he studied T cell immunology and identified the first delta chain protein product of the recently discovered gamma/delta T cell. Since graduating from UC Berkeley, he has been focused on the development of commercially viable approaches and business strategies for bringing cell therapies, gene-modified cell therapies and regenerative medicine from the bench to the clinic and into commercial use over the past three decades.

Positions